1. Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time.
- Author
-
Odak, Ivan, Bayir, Lâle M., Riemann, Lennart, Sikora, Ruth, Schneider, Jessica, Yankai Xiao, Möhn, Nora, Skripuletz, Thomas, Beutel, Gernot, Eder, Matthias, Ganser, Arnold, Förster, Reinhold, Schultze-Florey, Christian R., and Koenecke, Christian
- Subjects
CD19 antigen ,T cells ,IMMUNOPHENOTYPING ,DIFFUSE large B-cell lymphomas - Abstract
Variability or stability might have an impact on treatment success and toxicity of CD19 CAR T-cells. We conducted a prospective observational study of 12 patients treated with Tisagenlecleucel for CD19
+ B-cell malignancies. Using a 31-color spectral flow cytometry panel, we analyzed differentiation stages and exhaustion markers of CAR T-cell subsets prior to CAR T-cell infusion and longitudinally during 6 months of follow-up. The majority of activation markers on CAR T-cells showed stable expression patterns over time and were not associated with response to therapy or toxicity. Unsupervised cluster analysis revealed an immune signature of CAR T-cell products associated with the development of immune cell-associated neurotoxicity syndrome. Warranting validation in an independent patient cohort, in-depth phenotyping of CAR T-cell products as well as longitudinal monitoring post cell transfer might become a valuable tool to increase efficacy and safety of CAR T-cell therapy. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF